Table 2.

Relation between variants in PSA/KLK3 and prostate cancer in the entire family-based study sample, stratified by disease aggressiveness

KLK3/PSAEntire sampleLow aggressive*High aggressive
Cases/controlsOR (95% CI)PCases/controlsOR (95% CI)PCases/controlsOR (95% CI)P
Genotypes
A−158G
    AA124 of 1241.0057 of 711.0061 of 521.00
    GA196 of 2360.81 (0.52-1.26)0.3484 of 971.40 (0.66-2.99)0.3899 of 1220.62 (0.34-1.14)0.12
    GG119 of 1190.95 (0.55-1.64)0.8547 of 392.71 (1.06-6.94)0.0465 of 660.60 (0.28-1.30)0.19
A−4643G
    AA266 of 2811.00124 of 1341.00132 of 1341.00
    AG141 of 1630.87 (0.56-1.34)0.5250 of 600.89 (0.44-1.79)0.7476 of 890.84 (0.46-1.52)0.56
    GG32 of 351.03 (0.47-2.27)0.9414 of 132.11 (0.59-7.57)0.2517 of 170.91 (0.34-2.44)0.84
T−5412C
    TT259 of 2731.00121 of 1331.00127 of 1261.00
    TC160 of 1840.87 (0.56-1.36)0.5559 of 671.08 (0.53-2.17)0.8487 of 1020.78 (0.43-1.43)0.42
    CC20 of 220.99 (0.44-2.22)0.988 of 72.01 (0.51-7.89)0.3211 of 120.80 (0.28-2.26)0.67
Diplotypes
A−158G-A−4643G-T−5412C
    AAT/AAT117 of 1111.0055 of 651.0057 of 451.00
    AAT/GAT102 of 1240.72 (0.43-1.21)0.2248 of 611.56 (0.63-3.89)0.3451 of 650.50 (0.25-0.99)0.05
    AAT/GGC83 of 960.74 (0.42-1.30)0.3031 of 391.06 (0.42-2.62)0.9144 of 490.60 (0.27-1.29)0.19
    GAT/GAT36 of 300.93 (0.44-1.99)0.8617 of 122.42 (0.70-8.41)0.1618 of 140.65 (0.22-1.93)0.44
    GAT/GGC52 of 570.72 (0.38-1.37)0.3218 of 162.27 (0.77-6.67)0.1429 of 360.41 (0.17-0.96)0.04
    GGC/GGC18 of 200.83 (0.33-2.05)0.688 of 63.48 (0.88-13.7)0.079 of 110.46 (0.14-1.49)0.20
    Composites§31 of 410.56 (0.26-1.26)0.1511 of 180.43 (0.06-3.25)0.6817 of 200.48 (0.17-1.34)0.16
GGC
    None270 of 2901.00125 of 1391.00133 of 1371.00
    One copy151 of 1690.96 (0.61-1.49)0.8455 of 621.13 (0.57-2.24)0.7383 of 920.90 (0.49-1.65)0.73
    Two copies18 of 201.11 (0.47-2.59)0.818 of 62.90 (0.75-11.3)0.129 of 110.80 (0.26-2.44)0.70
  • * Includes cases with Gleason score <7 and tumor stage <T2C and their brothers.

  • Includes cases with Gleason score ≥7 and/or tumor stage ≥T2C and their brothers.

  • Adjusted for age.

  • § Composites include AAT/AAC, AAT/GGT, AAC/AGT, AAC/GAT, AGT/AGT, GAT/GAC, GAT/GGT, GGC/AAC, GGC/AGT, GGC/GAC, GGC/GGT.

  • Presence of haplotype GGC.